亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药

已收盘 08-27 16:08:31

36.920

+3.980

+12.08%

最高37.360	最低32.520	成交量481.26万
今开32.960	昨收32.940	日振幅14.69%
总市值138.08亿	流通市值138.08亿	总股本3.74亿
成交额1.69亿	换手率1.29%	流通股本3.74亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药","latestPrice":36.92,"timestamp":1787818111008,"preClose":32.94,"halted":0,"volume":4812638,"delay":0,"changeRate":0.12082574377656358,"floatShares":374000000,"shares":374000000,"eps":-3.49,"marketStatus":"已收盘","change":3.98,"latestTime":"08-27 16:08:31","open":32.96,"high":37.36,"low":32.52,"amount":169052294,"amplitude":0.146934,"askPrice":36.94,"askSize":1700,"bidPrice":36.92,"bidSize":18400,"shortable":3,"etf":0,"ttmEps":-4.526,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":5,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":32.94,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"volumeRatio":1.085768,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855/tweets","defaultTab":"tweets","newsList":[{"id":"1169928718","title":"异动解读｜亚盛医药盘中上涨13.18%，中期业绩商业化放量叠加券商首予增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1169928718","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169928718?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:59","pubTimestamp":1787817558,"startTime":"0","endTime":"0","summary":"8月27日，亚盛医药盘中上涨13.18%，报37.26港元，成交额1.66亿港元。消息面上，公司于8月20日公布中期业绩，上半年实现总收入3.02亿元人民币，同比增长29%；产品销售收入2.82亿元，同比增长33%，耐立克与利生妥双引擎驱动商业化持续放量。此外，国泰海通证券首予公司\"增持\"评级，目标价59.09港元，预计全年营收10.15亿元，同比增长约77%。公司近期还聘任CBO及CCO两位高管，加速海外商业化布局，全球注册III期临床同步推进，基本面催化集中释放。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药盘中上涨，商业化放量叠加券商首予增持","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662076169","title":"中金：维持亚盛医药(06855.HK)跑赢行业评级 目标价45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662076169","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662076169?lang=zh_cn&edition=full","pubTime":"2026-08-26 10:45","pubTimestamp":1787712337,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660347943","title":"亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2660347943","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660347943?lang=zh_cn&edition=full","pubTime":"2026-08-20 07:36","pubTimestamp":1787182583,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，亚盛医药今日公布2026年中期业绩。2026年上半年，公司实现总收入3.02亿元人民币，同比增长29%。在耐立克与利生妥两大商业化产品的双引擎驱动下，公司自我造血能力持续加强。报告期内，公司产品销售收入达到人民币2.82亿元，同比增长33%。截至报告期末，公司总货币资金约19亿元人民币，资金储备充足，为全球研发与商业化拓展提供坚实支撑。亚盛医药正全面快速推进这些全球注册III期临床研究，全球创新将迎来收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1574","06855","AAPG","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130393455","title":"亚盛医药（06855）公布2026年中期业绩：收入升29%至3.02亿元 研发投入近7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130393455","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130393455?lang=zh_cn&edition=full","pubTime":"2026-08-20 07:05","pubTimestamp":1787180755,"startTime":"0","endTime":"0","summary":"2026年8月19日，亚盛医药披露截至2026年6月30日止六个月未经审核中期业绩。期内公司收入3.022亿元，同比增长29.3%。其中，产品销售收入2.824亿元，较上年同期增长32.6%，为收入增长的主要动力。受费用增长影响，期内公司净亏损由上年同期的5.908亿元扩大至8.17亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659299118","title":"创新药概念集体回调 康方生物（09926）跌6.85%、维亚生物（01873）跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659299118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659299118?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:51","pubTimestamp":1786686711,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念集体回调，康方生物 跌6.85%，维亚生物跌6.33%，思路迪医药股份跌6.15%，恒瑞医药跌5.10%，晶泰控股跌4.88%，凯莱英跌4.67%，亚盛医药跌4.04%，药明康德跌3.94%，百济神州跌3.92%。西南证券表示，CXO+创新药放量领涨，8-9月有望迎来业绩+临床数据共振。从产业链的角度，CXO板块投融资改善明显，26H1中国/全球医疗健康投融资分别676.47亿元/2416.43亿元，ADC、多肽、细胞基因治疗等新药物形式赛道持续火热，头部CXO公司海外订单复苏明显。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873","BK1576","LU0634319403.HKD","LU0708995583.HKD","LNGR","LU0348783233.USD","LU1719994722.HKD","BK1141","01276","IE00B543WZ88.USD","LU0348784397.USD","LU0348827113.USD","LU2476274308.USD","LU0561508036.HKD","06978","KURE","LU1770034418.SGD","LU1961090484.USD","LU2778985437.USD","LU2045819591.USD","IBBQ","LU0828237510.HKD","LU1251922891.USD","LU0359202008.SGD","LU0052750758.USD","MEDX","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2476274720.SGD","02228","159992","BK1588","BK1617","LU2399975544.HKD","06160","09926","BK1574","LU0348766576.USD","02359","LU0307460666.USD","LU0327786744.USD","LU0572944931.SGD","LU0228659784.USD","LU2242644610.SGD","06821","LU0359201612.USD","06855","LU1720050803.USD","LU0588546209.SGD","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168288","title":"亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168288","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168288?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:13","pubTimestamp":1786626780,"startTime":"0","endTime":"0","summary":"中国苏州2026年8月13日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司管理层将出席于2026年8月17日-19日在上海浦东丽思卡尔顿酒店举办的Evercore第二届中国生物科技峰会。会议期间，公司管理层将参与由Evercore研究团队主持的炉边谈话，并开展一对一投资者交流会。因此，该等前瞻性陈述不应被视为对未来事件的预测。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","03069","KURE","BK1161","06855","EVR","BK4139","AAPG","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","01548","BK1583","02359","LU0880133367.SGD","IE00B5MMRT66.SGD","09969","IE00B031HY20.USD","BK1500","BK1515","IE00BZ08YT58.USD","LU1152091168.USD","BK1161","LU1226287875.USD","03692","LU2125910500.SGD","KURE","LU1303224171.USD","159992","BK1588","HK0000320223.HKD","LU0315179316.USD","LU0326950275.SGD","BK1576","LU1226287792.SGD","LU1951186391.HKD","06978","09688","IE00B543WZ88.USD","BK1617","IBBQ","LU1226288170.HKD","01093","LU2328871848.SGD","06855","LU1813983027.USD","MEDX","LU2488822045.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU0072913022.USD","BK1521","02268","HK0000306685.HKD","LNGR","LU2242644610.SGD","IE00BZ08YS42.EUR","02228","LU2039709279.SGD","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127890812","title":"亚盛医药7月股份变动月报：已发行股份微增至373,611,240股","url":"https://stock-news.laohu8.com/highlight/detail?id=1127890812","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127890812?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:15","pubTimestamp":1786018550,"startTime":"0","endTime":"0","summary":"2026年8月6日，亚盛医药集团发布截至2026年7月31日的股份变动月报表。公告显示，公司法定及注册股本维持为500,000,000股，每股面值0.0001美元，对应注册股本总额50,000美元，未发生变动。报告期内，亚盛医药集团已发行普通股由上月底的373,555,768股增加至373,611,240股，增加数量为55,472股，主要来自公司员工购股权计划的行使。根据公告，期权与激励计划方面，首次公开发售前购股权计划当月行使55,472股，筹资总额为港币554.72元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180485527","title":"亚盛医药宣布将于2026年8月19日披露中期业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1180485527","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180485527?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:02","pubTimestamp":1785931375,"startTime":"0","endTime":"0","summary":"亚盛医药（ASCENTAGE）计划于2026年8月19日公布其2026年上半年中期财务报告，并同步向市场提供公司业务进展的最新情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131497813","title":"亚盛医药（06855）董事会将于8月19日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1131497813","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131497813?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:36","pubTimestamp":1785929772,"startTime":"0","endTime":"0","summary":"亚盛医药集团8月5日公告称，公司董事会已排定于2026年8月19日（星期三）召开会议。届时，董事会将审议并（如适当）批准集团截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。此次董事会由主席兼执行董事杨大俊博士主持。公司提示，香港交易及结算所有限公司及香港联合交易所有限公司对公告内容概不负责，也未就其准确性或完整性作出任何陈述或保证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656419833","title":"亚盛医药聘任CBO、CCO分管全球业务拓展及海外商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656419833","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656419833?lang=zh_cn&edition=full","pubTime":"2026-08-03 09:11","pubTimestamp":1785719460,"startTime":"0","endTime":"0","summary":"8月3日，亚盛医药（06855）发布公告，公司宣布两项高管任命，聘任FaialMiyara博士担任CBO统筹全球业务拓展，JimZiegler出任CCO，负责大中华区以外全球产品商业化运营，二人直接向董事长兼首席执行官杨大俊博士汇报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829261521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829261521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0823414478.USD","BK1574","LU2357125470.USD","AAPG","LU2249611893.SGD","LU2294711713.HKD","LU2506951792.HKD","BK4009","BK1161","LU0823414551.USD","CCO","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346342","title":"亚盛医药(06855)任命Faiçal Miyara博士为首席业务拓展官，任命Jim Ziegler为首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656346342?lang=zh_cn&edition=full","pubTime":"2026-08-03 07:37","pubTimestamp":1785713832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，公司任命Faial Miyara博士为首席业务拓展官，负责亚盛医药的全球业务拓展工作;并任命Jim Ziegler为首席商务运营官，负责公司产品在大中华地区以外的全球市场的商业化运营。Miyara博士和Ziegler先生直接向公司董事长兼首席执行官杨大俊博士汇报。Miyara博士在全球大型制药公司和生物技术公司中拥有超过20年的肿瘤领域商务拓展经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197373836","title":"亚盛医药（06855.HK）新设两大高管职位　Faiçal Miyara任首席业务拓展官、Jim Ziegler任首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1197373836","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197373836?lang=zh_cn&edition=full","pubTime":"2026-08-03 07:35","pubTimestamp":1785713728,"startTime":"0","endTime":"0","summary":"2026年8月3日，亚盛医药集团发布自愿公告称，公司已任命Faial Miyara博士为首席业务拓展官，负责全球业务拓展；同时任命Jim Ziegler先生为首席商务运营官，主导公司产品在大中华区以外市场的商业化运营。两位高管均直接向公司董事长兼首席执行官杨大俊博士汇报。Miyara博士拥有逾20年肿瘤领域商务拓展经验，曾在IO Biotech担任首席业务拓展官及高管团队成员。亚盛医药董事会表示，此次人事任命旨在强化公司全球业务拓展及海外商业化能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145932645","title":"亚盛医药重磅任命：DR. FaiÇAl Miyara出任首席商务官，Jim Ziegler担任首席商业官","url":"https://stock-news.laohu8.com/highlight/detail?id=1145932645","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145932645?lang=zh_cn&edition=full","pubTime":"2026-08-03 07:31","pubTimestamp":1785713471,"startTime":"0","endTime":"0","summary":"亚盛医药（06855.HK）宣布两项关键高管任命。DR. FaiÇAl Miyara将掌舵首席商务官一职，而Jim Ziegler则被任命为首席商业官。此举标志着这家生物制药企业在全球商业化布局上迈出了战略性一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654992650","title":"【祝贺】亚盛医药杨大俊荣登《The Medicine Maker》2026全球最具影响力人物榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2654992650","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654992650?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:26","pubTimestamp":1785119160,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年7月27日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司董事长兼首席执行官杨大俊博士荣登国际知名医药产业媒体《The Medicine Maker》2026年度\"The Power List\"，在小分子领域TOP10名单中位居第三位。《The Medicine Maker》是全球制药产业链极具影响力的专业媒体，聚焦药物研发、CMC 工艺开发、产业化落地与新药商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","06855","BK4139","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181445115","title":"异动解读｜亚盛医药盘中下跌5.05%，2亿美元ATM融资计划持续引发稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1181445115","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181445115?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:03","pubTimestamp":1784873038,"startTime":"0","endTime":"0","summary":"7月24日，亚盛医药盘中下跌5.05%，报35.32港元/股，成交额3853.96万港元。消息面上，公司此前于7月20日向美国SEC提交F-3表格注册声明，拟通过ATM计划按市价发售最多2亿美元美国存托股份，销售代理包括花旗、德意志银行及BTIG。该发售须待港交所批准豁免上市规则后方可实施。以公司当前约140亿港元市值计算，2亿美元潜在新股发行对现有股东构成明显稀释压力，叠加生物科技板块近期整体偏弱，市场情绪持续承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182220503","title":"异动解读｜亚盛医药盘中下跌5.01%，2亿美元ATM融资计划引发稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1182220503","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182220503?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:16","pubTimestamp":1784600162,"startTime":"0","endTime":"0","summary":"7月21日，亚盛医药盘中下跌5.01%，报34.54港元/股，成交额5051.24万港元。所得款项净额将用于奥雷巴替尼及利沙托克拉的商业化、临床试验及营运资金。该发售须待港交所批准豁免上市规则后方可实施。以公司当前约133亿港元市值计算，2亿美元的潜在新股发行对现有股东构成一定稀释压力，叠加此前7月17日生物科技板块整体回调，市场情绪偏弱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652925116","title":"亚盛医药(06855.HK)向美国SEC递交F-3注册文件 拟发行最高2亿美元美国存托股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652925116","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652925116?lang=zh_cn&edition=full","pubTime":"2026-07-19 19:40","pubTimestamp":1784461202,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198157516","title":"亚盛医药集团(06855)拟在美启动最高2亿美元ATM发售计划并申请港交所豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=1198157516","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198157516?lang=zh_cn&edition=full","pubTime":"2026-07-19 19:20","pubTimestamp":1784460044,"startTime":"0","endTime":"0","summary":"2026年7月20日，亚盛医药集团（06855）公告称，于美国东部时间当日作为“知名成熟发行人”向美国证券交易委员会（SEC）提交一份F-3表格自动储架注册声明（注册编号333-297559）。该注册声明包含一份基础招股章程及一份销售协议招股章程，计划在纳斯达克按市价发售美国存托股份（ADS），募集资金总额最高不超过2亿美元。每份ADS代表公司4股每股面值0.0001美元的普通股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101035031","title":"异动解读｜亚盛医药盘中下跌8.49%，报36.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101035031","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101035031?lang=zh_cn&edition=full","pubTime":"2026-07-17 14:02","pubTimestamp":1784268132,"startTime":"0","endTime":"0","summary":"7月17日，亚盛医药盘中下跌8.49%，报36.0港元/股，成交额1.16亿港元。亚盛医药所在的生物科技行业中，整体跌幅显著，个股中，康方生物跌12.23%，三生制药跌9.66%，信达生物跌5.73%，科伦博泰生物跌5.53%，百济神州跌2.15%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.0529},{"period":"1month","weight":-0.084},{"period":"3month","weight":-0.1211},{"period":"6month","weight":-0.2977},{"period":"1year","weight":-0.6055},{"period":"ytd","weight":-0.3696}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0259},{"period":"6month","weight":-0.0367},{"period":"1year","weight":0.005},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.714286,"avgChangeRate":0.098263},{"month":5,"riseRate":0.428571,"avgChangeRate":0.029409},{"month":6,"riseRate":0.714286,"avgChangeRate":0.240354},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.06344},{"month":8,"riseRate":0.714286,"avgChangeRate":0.040086},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药","nameEN":"ASCENTAGE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,06855,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}